Close Menu

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a worldwide licensing agreement with Philips for the rights to manufacture and market Philips' recently validated phosphodiesterase-4D7 prostate cancer biomarker as a prognostic test.

The financial terms of the agreement have not been disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.